CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.
about
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesModulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancerPhase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.Prospects for combined use of oncolytic viruses and CAR T-cells.Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF-α and IFN-γ Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft Models.Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization.Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.From Benchtop to Bedside: A Review of Oncolytic Virotherapy.Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 BlockadeThe Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor MicroenvironmentSynergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virusModifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
P2860
Q26775030-2A0179D2-51E2-4B60-B635-AB65F0AF319DQ33679505-E1FFCCEC-FB38-4ED7-9683-16ED11E17A01Q37225501-1E593BE7-05E7-4348-9AA1-0B677F0B717BQ37256174-2F6FDFCC-111B-438A-B952-06FEACA20FE8Q37736296-B6FD5850-848C-485F-8435-5F8D18488AE0Q41688010-B8FA6D2C-A030-44AB-B563-9F4F9B830BBDQ45931583-28E2632C-5A88-442E-899B-FF295C07C1E5Q47103891-600A8840-6A9E-4D40-A443-28D62FB32F86Q50058491-2F5D3080-8CED-42CE-ABEF-B5E032092633Q51007512-222B24CB-224A-41A4-9EB0-C6F7F983B61CQ52699883-31F310FE-4186-4F7D-BCBB-9BFBD0AE27B8Q53272922-19449705-BBC7-4BFC-9AAB-E19CCE4E8335Q56967396-0DF8A594-46F7-4ABD-9BCD-C44281522711Q57492022-1C47B277-423D-4D47-AF29-E1472C63277FQ58565390-74358012-ADD5-4A5F-ACBA-0BEF1FDB8DDEQ58586410-5952ACAC-4690-4421-BC3E-A45005ACF02D
P2860
CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CXCL11-Armed oncolytic poxviru ...... enhanced therapeutic efficacy.
@en
type
label
CXCL11-Armed oncolytic poxviru ...... enhanced therapeutic efficacy.
@en
prefLabel
CXCL11-Armed oncolytic poxviru ...... enhanced therapeutic efficacy.
@en
P2093
P2860
P1433
P1476
CXCL11-Armed oncolytic poxviru ...... enhanced therapeutic efficacy.
@en
P2093
David L Bartlett
Pawel Kalinski
Roshni Ravindranathan
Z Sheng Guo
Zuqiang Liu
P2860
P304
P356
10.1080/2162402X.2015.1091554
P577
2015-10-29T00:00:00Z